Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APGE Apogee Therapeutics

Closed 12-18 16:00:00 EST

77.35

+1.85

+2.45%

盘后77.35

+0.000.00%

16:10 EST

High78.14	Low74.54	Vol910.73K
Open75.77	D1 Closing75.50	Amplitude4.77%
Mkt Cap5.28B	Tradable Cap3.67B	Total Shares68.32M
T/O69.96M	T/O Rate1.92%	Tradable Shares47.47M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APGE","market":"US","secType":"STK","nameCN":"Apogee Therapeutics","latestPrice":77.35,"timestamp":1766091600000,"preClose":75.5,"halted":0,"volume":910728,"hourTrading":{"tag":"盘后","latestPrice":77.35,"preClose":77.35,"latestTime":"16:10 EST","volume":12236,"amount":946454.6,"timestamp":1766092204389},"delay":0,"floatShares":47471600,"shares":68320200,"eps":-4.361393,"marketStatus":"Closed","change":1.85,"latestTime":"12-18 16:00:00 EST","open":75.77,"high":78.135,"low":74.5366,"amount":69961793.371344,"amplitude":0.047661,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.361393,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":75.5,"preHourTrading":{"tag":"盘前","latestPrice":75.51,"preClose":75.5,"latestTime":"08:49 EST","volume":11,"amount":830.61,"timestamp":1766065798453},"postHourTrading":{"tag":"盘后","latestPrice":77.35,"preClose":77.35,"latestTime":"16:10 EST","volume":12236,"amount":946454.6,"timestamp":1766092204389},"volumeRatio":0.960438,"impliedVol":0.5442,"impliedVolPercentile":0.176},"requestUrl":"/m/hq/s/APGE/tweets","defaultTab":"tweets","newsList":[{"id":"2592722918","title":"Apogee Therapeutics Initiated at Overweight by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2592722918","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592722918?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:42","pubTimestamp":1765978920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APGE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 08:42 ET (13:42 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE"],"gpt_icon":0},{"id":"2592920659","title":"Stephens Initiates Coverage on Apogee Therapeutics With Overweight Rating, $95 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2592920659","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592920659?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:21","pubTimestamp":1765974061,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics (APGE) has an average rating of Buy and mean price target of $92.54, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APGE"],"gpt_icon":0},{"id":"2592994926","title":"BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592994926","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592994926?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:45","pubTimestamp":1765971925,"startTime":"0","endTime":"0","summary":"BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026** Brokerage RBC Capital Markets says biotech sector has strongly rebounded since April 2025, helped by good ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN0QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130102774.USD","LU1571399168.USD","BK","LU0648001328.SGD","LU1699723380.USD","BK4559","BK4139","XENE","LU0477156953.USD","LU1201861249.SGD","APGE","LU0053671581.USD","BK4086","LU0980610538.SGD","BK4588","BK4585","BK4135","KYMR","LU0130517989.USD","APOG"],"gpt_icon":0},{"id":"2592964351","title":"U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2592964351","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592964351?lang=en_us&edition=fundamental","pubTime":"2025-12-17 15:13","pubTimestamp":1765955630,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range ResourcesDec 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Airb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL8N3XN0FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEE","BETA","BAC","LNT","LU1061106388.HKD","ADSK","AMPL","SAM","ATO","CHRW","AVTR","ADC","BDX","IE00BN29S564.USD","LU2106854487.HKD","IE00BJJMRZ35.SGD","LU0957791311.USD","EAT","AMAT","BRZE","AGYS","AWK","BK4197","LU0106831901.USD","BALY","ARVN","BK4588","FOLD","ALLY","ARWR","AXP","BK4581","AJG","BK4209","BSX","ALB","CCCC","CCL","APGE","AAP","ABNB","AEP","AIR","LU1280957306.USD","ANAB","ASAN","BBY","BLK","WHD","BK4076"],"gpt_icon":0},{"id":"2591680494","title":"Apogee Therapeutics CEO Michael Henderson Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591680494","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591680494?lang=en_us&edition=fundamental","pubTime":"2025-12-13 09:00","pubTimestamp":1765587644,"startTime":"0","endTime":"0","summary":"Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251213:nNDL9fMTxk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apogee Therapeutics CEO Michael Henderson Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2590158483","title":"Apogee Therapeutics Inc : Deutsche Bank Initiates Coverage With Buy Rating and Target Price  $103","url":"https://stock-news.laohu8.com/highlight/detail?id=2590158483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590158483?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:07","pubTimestamp":1765368422,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nAQN2LCXCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2590054413","title":"U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590054413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590054413?lang=en_us&edition=fundamental","pubTime":"2025-12-10 14:43","pubTimestamp":1765349009,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer Dec 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including JP Morgan, Pepsi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nL4N3XG0E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANF","APGE","DE","CAT","CAPR","AU","CARR","ASMB","AVAV","CF","CHD","CBRL","ASO","IE00B19Z9Z06.USD","BDX","ANDE","BWB","CMCSA","AMRZ","LU1868837136.USD","PLAY","IE00B3PB1722.GBP","CPB","T","LU0096364046.USD","AMGN","BRZE","LU0942090050.USD","LU2746668974.SGD","APD","CNM","CVS","BIIB","DBI","LU1868836914.USD","BTI","AVBP","LU0321505868.SGD","BLLN","CMC","LU2133065610.SGD","ELAN","SG9999011175.SGD","COF","ABBV","SATS","BMY","AZO","IE00BDGV0183.EUR","IE00B894F039.SGD"],"gpt_icon":1},{"id":"2589846932","title":"Apogee Therapeutics Chief Medical Officer Carl Dambkowski Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589846932","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589846932?lang=en_us&edition=fundamental","pubTime":"2025-12-06 09:04","pubTimestamp":1764983062,"startTime":"0","endTime":"0","summary":"Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDLbD8f5w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apogee Therapeutics Chief Medical Officer Carl Dambkowski Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2589846621","title":"Apogee Therapeutics CFO Jane Henderson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589846621","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589846621?lang=en_us&edition=fundamental","pubTime":"2025-12-06 09:02","pubTimestamp":1764982958,"startTime":"0","endTime":"0","summary":"Jane Henderson, Chief Financial Officer of Apogee Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL8nhfdQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2588065890","title":"Does Positive APG333 Data and $345 Million Raise Redefine the Bull Case for Apogee Therapeutics (APGE)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588065890","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588065890?lang=en_us&edition=fundamental","pubTime":"2025-12-03 02:34","pubTimestamp":1764700463,"startTime":"0","endTime":"0","summary":"In recent days, Apogee Therapeutics announced positive interim Phase 1 results for its experimental antibody APG333 and completed a public offering that raised approximately US$345 million through the sale of over 8 million shares. \nThis combination of encouraging clinical data and a successful capital raise highlights strong investor interest and confidence in Apogee’s clinical pipeline.\nWe’ll explore how the promising potential of APG333 as indicated by interim trial results shapes Apogee...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apge/apogee-therapeutics/news/does-positive-apg333-data-and-345-million-raise-redefine-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apge/apogee-therapeutics/news/does-positive-apg333-data-and-345-million-raise-redefine-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2587775544","title":"Apogee Therapeutics CFO Jane Henderson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2587775544","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587775544?lang=en_us&edition=fundamental","pubTime":"2025-11-29 09:00","pubTimestamp":1764378054,"startTime":"0","endTime":"0","summary":"Jane Henderson, Chief Financial Officer of Apogee Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251129:nNDL8kgkB6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apogee Therapeutics CFO Jane Henderson Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2585591104","title":"Positive Early APG333 Data Could Be a Game Changer for Apogee Therapeutics (APGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585591104","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585591104?lang=en_us&edition=fundamental","pubTime":"2025-11-23 08:24","pubTimestamp":1763857444,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics recently reported wider losses for the third quarter and nine months ended September 30, 2025, while also announcing positive interim Phase 1 results for its APG333 antibody candidate, which was well tolerated up to 1,000 mg and supports less frequent dosing intervals.\nThe encouraging clinical data for APG333, alongside updates on the company's advanced antibody programs, highlights Apogee’s efforts to address unmet needs in immunology and inflammation markets despite...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apge/apogee-therapeutics/news/positive-early-apg333-data-could-be-a-game-changer-for-apoge","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apge/apogee-therapeutics/news/positive-early-apg333-data-could-be-a-game-changer-for-apoge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2583541759","title":"Apogee Therapeutics CEO Michael Henderson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583541759","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583541759?lang=en_us&edition=fundamental","pubTime":"2025-11-14 09:24","pubTimestamp":1763083493,"startTime":"0","endTime":"0","summary":"Michael Thomas Henderson, Chief Executive Officer and Director of Apogee Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL8vbGYk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apogee Therapeutics CEO Michael Henderson Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APGE"],"gpt_icon":0},{"id":"2582345868","title":"Apogee Therapeutics Reports Q3 2025 Financial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2582345868","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582345868?lang=en_us&edition=fundamental","pubTime":"2025-11-12 12:12","pubTimestamp":1762920737,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics, Inc. ( ($APGE) ) has released its Q3 earnings. Here is a breakdown of the information Apogee Therapeutics, Inc. presented to i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-reports-q3-2025-financial-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-reports-q3-2025-financial-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PRGS","LU2065732104.USD","BK4097","APGE"],"gpt_icon":0},{"id":"2582312706","title":"RBC Capital Sticks to Their Buy Rating for Apogee Therapeutics (APGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582312706","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582312706?lang=en_us&edition=fundamental","pubTime":"2025-11-12 09:48","pubTimestamp":1762912095,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on Apogee Therapeutics on November 10 and set a price target of $70.00. The company’s sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-apogee-therapeutics-apge-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-apogee-therapeutics-apge-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"gpt_icon":0},{"id":"1159855373","title":"Stock Track | Apogee Therapeutics Soars 5.28% Following Mizuho Securities' Bullish Stance","url":"https://stock-news.laohu8.com/highlight/detail?id=1159855373","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159855373?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:22","pubTimestamp":1762874540,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics (APGE) stock is soaring 5.28% in Tuesday's trading session, buoyed by a positive analyst report from Mizuho Securities. The surge comes as investors react to the reaffirmation of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["APGE"],"gpt_icon":0},{"id":"1148776358","title":"Stock Track | Apogee Therapeutics Soars 5.28% Following Mizuho Securities' Buy Rating and $105 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1148776358","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148776358?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:22","pubTimestamp":1762874538,"startTime":"0","endTime":"0","summary":"Shares of Apogee Therapeutics (APGE) are soaring 5.28% in intraday trading on Tuesday, as investors react positively to a reaffirmed Buy rating from Mizuho Securities. The surge comes after analyst...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["APGE"],"gpt_icon":0},{"id":"2582369766","title":"Mizuho Securities Sticks to Their Buy Rating for Apogee Therapeutics (APGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582369766","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582369766?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:45","pubTimestamp":1762865140,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Joseph Catanzaro maintained a Buy rating on Apogee Therapeutics today and set a price target of $105.00. Catanzaro covers...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-apogee-therapeutics-apge-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-apogee-therapeutics-apge-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE","MFG"],"gpt_icon":0},{"id":"2582980843","title":"Apogee Therapeutics Reports Positive Interim Results for APG333 Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2582980843","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582980843?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:28","pubTimestamp":1762788530,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics  said Monday that interim phase 1 data for its APG333 antibody \"exceeded trial objectives,\" demonstrating a half-life of about 55 days, supporting potential dosing every three and six months.APG333, which is being developed for the treatment of inflammatory and immunology conditions, was also well tolerated across all cohorts, with doses of up to 1,000 mg, the company said.Apogee shares were 2.7% higher in recent trading.Price: 56.25, Change: +1.54, Percent Change: +2.81","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2582808630","title":"Positive Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trials and Strategic Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2582808630","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582808630?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:15","pubTimestamp":1762787717,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating today. Tyler Van Buren has given his Buy ra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-buy-rating-for-apogee-therapeutics-driven-by-promising-clinical-trials-and-strategic-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-buy-rating-for-apogee-therapeutics-driven-by-promising-clinical-trials-and-strategic-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apogeetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":0.1646},{"period":"3month","weight":0.9646},{"period":"6month","weight":0.7993},{"period":"1year","weight":0.57},{"period":"ytd","weight":0.6667}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.","exchange":"NASDAQ","name":"Apogee Therapeutics","nameEN":"Apogee Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Apogee Therapeutics(APGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Apogee Therapeutics,APGE,Apogee Therapeutics股票,Apogee Therapeutics股票老虎,Apogee Therapeutics股票老虎国际,Apogee Therapeutics行情,Apogee Therapeutics股票行情,Apogee Therapeutics股价,Apogee Therapeutics股市,Apogee Therapeutics股票价格,Apogee Therapeutics股票交易,Apogee Therapeutics股票购买,Apogee Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Apogee Therapeutics(APGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}